AR011669A1 - A COMPOUND DERIVED FROM 5-AMINOALCOXI-1,4-DIHIDROQUINOXALIN-2,3-DIONAS REPLACED, PHARMACEUTICAL COMPOSITION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT - Google Patents

A COMPOUND DERIVED FROM 5-AMINOALCOXI-1,4-DIHIDROQUINOXALIN-2,3-DIONAS REPLACED, PHARMACEUTICAL COMPOSITION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Info

Publication number
AR011669A1
AR011669A1 ARP980100618A ARP980100618A AR011669A1 AR 011669 A1 AR011669 A1 AR 011669A1 AR P980100618 A ARP980100618 A AR P980100618A AR P980100618 A ARP980100618 A AR P980100618A AR 011669 A1 AR011669 A1 AR 011669A1
Authority
AR
Argentina
Prior art keywords
manufacture
pharmaceutical composition
dihidroquinoxalin
aminoalcoxi
dionas
Prior art date
Application number
ARP980100618A
Other languages
Spanish (es)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of AR011669A1 publication Critical patent/AR011669A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se relaciona con compuestos derivados de la formula (I) 5-aminoetoxi-1,4- dihidroquinoxalin-2,3-dionas sustituidas, en la cual R1 y R2 esindependientemente seleccionada entre hidrogeno, un grupo alquilo de cadena recta y ramificada con hasta 10átomos de carbono, o (CH2)mAr, donde Ar esfenilo, naftilo, o tienilo, cada uno de ellos optativamente sustituido por uno o dos sustituyentes seleccionados independientemente entre alquilo C1-C6halogeno, alcoxido C1-C6 y trifluorometilo; o NR1R2es 1,2,3,4- tetrahidroquinolin-1-ilo o 1,2,3,4-tetrahidroisoquinolin-1-ilo; m es 1-5; nes 1 o 2; Y es hidrogeno, halogeno, alquilo C1-C6 y alcoxi C1-C6; o las sales farmacéuticamente aceptables de los mismos, que son agonistas de la dopaminaD2 y por lo tanto son utiles en el tratamiento de las psicosis y la enfermedad de Parkinson. Además se describe una composicion farmacéutica que los comprendey un uso de dichos compuestos para la fabricacion de un medicamentoRelates to compounds derived from the formula (I) 5-aminoethoxy-1,4-dihydroquinoxalin-2,3-diones substituted, in which R1 and R2 are independently selected from hydrogen, a branched and straight-chain alkyl group with up to 10 atoms carbon, or (CH2) mAr, where Ar sphenyl, naphthyl, or thienyl, each optionally substituted by one or two substituents independently selected from C1-C6alkylhalogen, C1-C6alkoxide, and trifluoromethyl; or NR1R2 is 1,2,3,4-tetrahydroquinolin-1-yl or 1,2,3,4-tetrahydroisoquinolin-1-yl; m is 1-5; nes 1 or 2; Y is hydrogen, halogen, C1-C6 alkyl, and C1-C6 alkoxy; or the pharmaceutically acceptable salts thereof, which are dopamine D2 agonists and are therefore useful in the treatment of psychoses and Parkinson's disease. In addition, a pharmaceutical composition comprising them and a use of said compounds for the manufacture of a medicament are described.

ARP980100618A 1997-02-18 1998-02-11 A COMPOUND DERIVED FROM 5-AMINOALCOXI-1,4-DIHIDROQUINOXALIN-2,3-DIONAS REPLACED, PHARMACEUTICAL COMPOSITION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AR011669A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80132497A 1997-02-18 1997-02-18

Publications (1)

Publication Number Publication Date
AR011669A1 true AR011669A1 (en) 2000-08-30

Family

ID=25180799

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100618A AR011669A1 (en) 1997-02-18 1998-02-11 A COMPOUND DERIVED FROM 5-AMINOALCOXI-1,4-DIHIDROQUINOXALIN-2,3-DIONAS REPLACED, PHARMACEUTICAL COMPOSITION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Country Status (14)

Country Link
EP (1) EP0963372A1 (en)
JP (1) JP2001511805A (en)
KR (1) KR20000071162A (en)
CN (1) CN1248249A (en)
AR (1) AR011669A1 (en)
AU (1) AU722616B2 (en)
BR (1) BR9807230A (en)
CA (1) CA2278757A1 (en)
HU (1) HUP0001311A3 (en)
IL (1) IL131160A0 (en)
NZ (1) NZ336971A (en)
TW (1) TW434230B (en)
WO (1) WO1998035948A1 (en)
ZA (1) ZA981306B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285786B1 (en) 2008-06-16 2013-10-09 Merck Patent GmbH Quinoxalinedione derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179551C (en) * 1987-11-10 1996-10-30 Novo Nordisk As Analogous Process for Preparing Therapeutically Effective Quinoxaline Compounds
DK715888D0 (en) * 1988-12-22 1988-12-22 Ferrosan As QUINOXAL COMPOUNDS, THEIR PREPARATION AND USE
US4975430A (en) * 1989-06-16 1990-12-04 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University CNQX and its analogs as therapeutics for degenerative neural diseases
PT99864B (en) * 1990-12-21 1999-06-30 Schering Ag METHOD FOR PREPARING NEW PHARMACEUTICAL COMPOSITIONS CONTAINING QUISQUALATE RECEPTOR ANTAGONISTS
US5159083A (en) * 1990-12-28 1992-10-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; a class of dopamine receptor subtype specific ligands
ES2313714T3 (en) * 1992-06-22 2009-03-01 The Regents Of The University Of California ANTIGONISTS OF GLYCINE RECEPTORS AND USE OF THE SAME.
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
DK0707007T3 (en) * 1994-10-14 2002-03-18 Merck Patent Gmbh Amino (thio) ether derivatives as CNS active agents
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists

Also Published As

Publication number Publication date
AU722616B2 (en) 2000-08-10
CA2278757A1 (en) 1998-08-20
HUP0001311A2 (en) 2001-05-28
WO1998035948A1 (en) 1998-08-20
IL131160A0 (en) 2001-01-28
AU6035098A (en) 1998-09-08
EP0963372A1 (en) 1999-12-15
JP2001511805A (en) 2001-08-14
BR9807230A (en) 2000-04-25
ZA981306B (en) 1999-08-17
CN1248249A (en) 2000-03-22
HUP0001311A3 (en) 2001-07-30
NZ336971A (en) 2000-10-27
KR20000071162A (en) 2000-11-25
TW434230B (en) 2001-05-16

Similar Documents

Publication Publication Date Title
AR029766A1 (en) QUINASE INHIBITOR COMPOUND AND USE OF IT TO PREPARE A PHARMACEUTICAL COMPOSITION
SE0104334D0 (en) Therapeutic agents
EA200200571A1 (en) NEW COMPOSITION AND ITS APPLICATION
EA200300323A1 (en) DERIVATIVES OF GUANIDININOBENZAMIDE (OPTIONS), COMPOSITION (OPTIONS), METHOD OF TREATMENT OF MEDIATED DISTRIBUTIONS mc4-r
SE9504661D0 (en) New compounds
ATE445597T1 (en) ß2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USEß
PA8495101A1 (en) DERIVATIVES OF 13-METHYLERITROMYCIN
AR024998A1 (en) NEW RETINOIDS FOR THE TREATMENT OF THE DISEASE
DE69231298D1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
SE9903997D0 (en) New compounds
SE0300908D0 (en) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
AR018162A1 (en) SUBSTITUTED PIRROLS, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION
AR024840A1 (en) 5HT1 COMPOUNDS FOR ANTIDEPRESSIVE THERAPY; PHARMACEUTICAL COMPOSITIONS AND ITS USE IN THE PREPARATION OF MEDICINES.
AR010899A1 (en) OXAZOLIDINONES, A PROCEDURE FOR THEIR PREPARATION, THE USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, MEDICINES AND PREPARATIONS THAT CONTAIN THEM AND A PROCEDURE TO OBTAIN THESE PHARMACEUTICAL PREPARATIONS.
AR025351A1 (en) PAR SELECTIVE RETINOID AGONISTS
AR035006A1 (en) DERIVATIVE OF NAFTIRIDIN-DIBENZO [A, D] CICLOHEPTENO-10-ACETICO, PHARMACEUTICAL COMPOSITION, AND THE USE OF THAT DERIVATIVE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
PT99864A (en) METHOD FOR PREPARING NEW PHARMACEUTICAL COMPOSITIONS CONTAINING QUISQUALATE RECEPTOR ANTAGONISTS
CO4410322A1 (en) NEW CARBOXAMIDE COMPOUNDS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR013241A1 (en) DERIVATIVES OF AMINOETHYLPHENOXYACETIC ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH A DERIVATIVE, MEDICATION TO REDUCE PAIN AND PROMOTE THE ELIMINATION OF CALCULATIONS IN UROLITIASIS, USE OF SUCH A DERIVATIVE FOR THE MANUFACTURING OF DICATION
AR011669A1 (en) A COMPOUND DERIVED FROM 5-AMINOALCOXI-1,4-DIHIDROQUINOXALIN-2,3-DIONAS REPLACED, PHARMACEUTICAL COMPOSITION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
UY27324A1 (en) NEW NAPSILATE SALTS I
BR9406897A (en) Tetrahydroisoquinoline compounds pharmaceutical compositions process of analgesia or treatment of psychoses parkinson's disease leschnyan syndrome disorder of lack of attention or cognitive damage or in suppression of drug addiction or tardive dyskinesia and use of a compound
KR930010016A (en) Saccharin Derivatives, Protease Inhibitors
KR900014397A (en) Thieno-triazolo-diazepine sulfonyl derivatives, methods for their preparation and therapeutic compositions containing them
AR020773A1 (en) COMPOUND DERIVED FROM 3- (TETRAHYDROPIRIDIN-4-IL) INDOL, METHOD TO PREPARE IT, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, METHOD TO PREPARE SUCH COMPOSITION AND USE OF THE COMPOUND